Greater Bay Area International Clinical Trial Center Leads Latin American Healthcare Delegation on Visit to Kexing Biopharm

Article source：Sep 14,2026View： 153

On September 11, a Latin American healthcare delegation organized by the Guangdong–Hong Kong–Macao Greater Bay Area International Clinical Trial Center visited Kexing Biopharm for a site tour and exchange under the theme "Boundless Innovation · Smarter Health." The delegation brought together industry experts from healthcare institutions and corporate management in countries including Brazil, Argentina, Colombia, and Chile. The visit is not only a vivid example of the Greater Bay Area and Latin America deepening cooperation and pursuing shared development in biopharmaceuticals, but also a showcase of the international capabilities of Shenzhen's biopharmaceutical companies.

Dr. Qin Suofu, Vice President of the Company, accompanied the delegation on a tour of Kexing Biopharm's R&D center. During the subsequent meeting session, the head of the Company's Latin America business gave a detailed introduction to Kexing Biopharm's development history, its dual-engine "Innovation + Internationalization" strategy, and the achievements accumulated through its integrated R&D, manufacturing, and sales operations. The delegation took particular interest in the Company's R&D and innovation results. Dr. Qin presented the Company's recent innovation initiatives and technological breakthroughs to the guests, ranging from its 3KX core technology platform to more than a dozen global innovative drug pipelines. Among these, the K'Exosome delivery technology platform and the GB18 cancer cachexia pipeline prompted lively discussion. One of the participating experts remarked: "This visit gave us a full sense of the strength of Chinese pharmaceutical companies. Kexing Biopharm continues to identify unmet clinical needs and has built a rich innovative pipeline in areas such as oncology and autoimmune diseases. We look forward to Kexing Biopharm bringing more high-quality, effective medicines to the Latin American market to serve local doctors and patients."

Kexing Biopharm has already established subsidiaries in Brazil and Colombia and has built localized operating teams covering drug registration and marketing promotion. Taking this exchange as an opportunity, and drawing on more than 20 years of experience in taking biologics overseas, the Company will continue to explore opportunities for commercial cooperation with industry peers in Latin America.